Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
Authors' conclusion
Finerenone demonstrated treatment benefits in people with chronic kidney disease and type 2 diabetes, irrespective of treatment goals achieved at baseline.
Study context
- Population
- Participants with T2D and CKD, subgrouped by number of ADA treatment goals met at baseline (HbA1c ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, LDL-C < 1.81 mmol/L, use of SGLT2i or GLP-1 RA)randomized 1:1
- Comparison
- Finerenone vs placebo, by number of baseline treatment goals met
- Outcome
- Composite cardiovascular outcome by subgroups based on number of treatment goals achieved
Methodological detailsprespecified pooled analysis, participant-level data, randomized, double-blind, multicentre, phase III, exploratory subgroup analysis
- Prespecified pooled analysis
- Participant-level data
- Randomized
- Double-blind
- Multicentre
- Phase III
- Exploratory subgroup analysis
Pooled result
As reported in the abstract
Composite cardiovascular outcomes, events per 100 patient-years in placebo, by treatment goals met
Placebo, 0 treatment goals
6.0
Placebo, 1 treatment goal
5.1
Placebo, 2 treatment goals
4.3
Placebo, ≥ 3 treatment goals
3.5
Further pooled results
Baseline distribution of treatment goals met
- 0 treatment goals
- 29%
- 1 treatment goal
- 40%
- 2 treatment goals
- 24%
- ≥ 3 treatment goals
- 7%
Other outcomes (composite kidney, HF hospitalization or cardiovascular death, HF hospitalization)
- Similar patterns were observed for other outcomes
Safety
Treatment-emergent adverse events
- Safety profile of finerenone (vs placebo) was similar across subgroups
Original publication
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis. Diabetes Obes Metab. Published 24 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →